Ownership and insider activity for GRI Bio, Inc. (GRI): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis.
Price
| Price | $1.81 |
| Market Cap | $0M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2025-09-18 | Kelly Leanne | A-Award | 43,222 | $83K |
| 2025-09-18 | Szekeres David Leslie | A-Award | 39,897 | $77K |
| 2025-09-18 | Baker David Charles | A-Award | 23,605 | $46K |
| 2025-09-18 | SIMPSON CAMILLA V | A-Award | 23,605 | $46K |
| 2025-09-18 | Chaturvedi Vipin | A-Award | 43,222 | $83K |
| 2025-09-18 | Rongen Roelof | A-Award | 23,605 | $46K |
| 2025-09-18 | Hertz Walter Marc | A-Award | 103,067 | $199K |
| 2025-08-26 | Hertz Walter Marc | A-Award | 26,688 | $38K |
| 2025-08-26 | Szekeres David Leslie | A-Award | 10,276 | $14K |
| 2025-08-26 | Baker David Charles | A-Award | 5,994 | $8K |
Balance Sheet (10y)
| Year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $612652 | $3.8M | $109000 | $90000 | $9000 | $1.8M | $5.0M | $8.2M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $637639 | $3.9M | $674000 | $96000 | $312000 | $2.9M | $5.6M | $8.6M |
| Property, Plant & Equipment | $1592 | $353902 | $281000 | $117000 | $71000 | $22000 | $124000 | $74000 |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $639231 | $4.3M | $955000 | $218000 | $383000 | $3.0M | $5.7M | $8.7M |
| Accounts Payable | $286613 | $246329 | $1.2M | $57000 | $1.3M | $1.4M | $897000 | $1.8M |
| Short-term Debt | 0 | $85665 | $152000 | $3.5M | $602000 | 0 | 0 | 0 |
| Total Current Liabilities | $486292 | $807498 | $2.2M | $4.9M | $2.0M | $2.7M | $1.6M | $2.6M |
| Long-term Debt | 0 | 0 | $14000 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | $486292 | $1.1M | $2.4M | $4.9M | $2.0M | $2.7M | $1.7M | $2.7M |
| Retained Earnings | -$4.3M | -$7.8M | -$12.6M | -$15.3M | -$18.5M | -$31.5M | -$39.7M | -$51.7M |
| Total Equity | $152939 | $3.2M | -$1.5M | -$4.7M | -$1.6M | $259000 | $4.0M | $6.0M |
| Total Debt | 0 | $340021 | $336000 | $3.6M | $673000 | $14000 | $119000 | $71000 |
| Net Debt | -$612652 | -$3.5M | $227000 | $3.5M | $664000 | -$1.8M | -$4.9M | -$8.2M |
| Working Capital | $151347 | $3.1M | -$1.6M | -$4.8M | -$1.7M | $237000 | $4.0M | $5.9M |
Financial Health
| Debt / Equity | 0.00 |
| Current Ratio | 10.30 |
Profitability
| Return on Equity | -134.03% |
| Return on Invested Capital | -93.76% |
| Return on Assets | -84.88% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ABP · BDRX · CANF · CLDI · CNSP · GNPX · INM
Explore sector: Healthcare · Biotechnology
More sections of GRI: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks